Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health Plc | Stock Exchange Release | June 09, 2025 at 16:15:00 EEST

Nightingale Health Plc’s (“Nightingale Health”) Board of Directors has resolved to launch a stock option program for the company’s newest management team member Janna Ranta in accordance with the established practice for stock option rights in the management team.

The right to subscribe for shares is earned solely based on an increase in Nightingale Health’s market capitalization.

The purpose of Nightingale Health’s stock option programs is to bind the option holders to the company’s economic growth and the development of its market capitalization, as well as create a long-term relationship between the company and its option holders that benefits the company economically and operationally. The decision to launch the new stock option program was made based on the authorization granted by the Extraordinary General Meeting held on 18 February 2021.

Each option right entitles the option holder to subscribe for one Series B share. The subscription price of each share is EUR 2.50 per share. The total number of stock option rights that can be issued under the new stock option programs is 339,800, entitling the holder to subscribe for a maximum of 339,800 Series B shares.

The right to subscribe for shares is earned upon reaching the following market capitalization steps, calculated with the volume weighted average price: 1,000 million, 1,250 million and 1,500 million euros. The share subscription period for the stock option program ends on 31 May 2035.

About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/